Roche Doubles Down on Hansoh With 5 Billion ADC Alliance

Roche Doubles Down on Hansoh With $15 Billion ADC Alliance

A $510 Million Handshake Opens a $15 Billion Wager

Roche is going back to its favorite Chinese ADC partner, and this time the checkbook is far bigger. Hansoh Pharmaceutical announced on October 19 that its subsidiaries have signed a strategic collaboration and licensing agreement with Roche unit F. Hoffmann-La Roche covering a broad portfolio of antibody-drug conjugate programs, Reuters reported. Hansoh will receive $400 million upfront plus $110 million on the first anniversary of the deal, and is eligible for potentially more than $15 billion in development, regulatory and commercialization milestones, plus tiered royalties on future sales, according to the company's exchange filing and corporate announcement carried by Marketscreener.

Two Assets in Hand, More Targets to Be Named by Roche

The collaboration spans two ADC programs already in preclinical development at Hansoh, plus multiple additional programs built around targets proposed by Roche but powered by Hansoh's proprietary ADC technology platform, Fierce Biotech and BioSpace reported. In plain terms, Roche supplies the disease targets and late-stage development muscle, while Hansoh supplies the ADC engineering that has made it one of China's most sought-after biotech partners.

Hansoh Runs the Early Miles, Roche Takes the Global Baton

Under the agreed division of labor, Hansoh will lead early development of each program through the completion of global Phase Ia trials, Reuters reported. Roche then assumes responsibility for further development and commercialization worldwide, excluding mainland China, Hong Kong, Macau and Taiwan, where Hansoh retains full rights to develop, register and sell the medicines. Hansoh also holds an option to participate in the development of up to two programs outside those home markets. "Expanding our strategic collaboration with Hansoh marks an important step in advancing our ADC vision," Boris L. Zaïtra, head of corporate business development at Roche, said in a statement quoted by Quartz.

From an $80 Million Pilot to a Platform Bet

The new pact is the second ADC deal between the two companies. About a year ago, Roche paid $80 million upfront and pledged up to $1.45 billion in biobucks for the ex-China rights to HS-20110, a CDH17-targeted ADC then already in Phase 1 testing in China and the United States for colorectal cancer and other solid tumors, Fierce Biotech reported. The leap from a single-asset license to a platform-wide portfolio, and from an $80 million upfront to $400 million, signals how far Roche's confidence in Hansoh's technology has come in twelve months.

GSK's Success Is Hansoh's Best Advertisement

Hansoh's reputation rests on clinical validation, not promises. At the end of 2023, Britain's GSK paid $185 million upfront for access to Hansoh's HS-20093, also known as risvutatug rezetecan, in a deal that could surpass $1.5 billion, BioSpace reported. The B7-H3-directed ADC later posted a median overall survival of 18.5 months in a pivotal small-cell lung cancer trial, Fierce Biotech reported, positioning it as a potential challenger to Amgen and Merck in the lung cancer arena. With collaborations spanning Roche, GSK, Merck and Regeneron, Hansoh has earned its billing as China's ADC powerhouse.

Roche's Oncology Pipeline Keeps a Chinese Address

For Roche, the deal extends a busy stretch of China-facing dealmaking. In August its Genentech unit struck an ADC agreement with DualityBio worth up to $1 billion, Reuters reported, and last week Roche licensed an experimental obesity therapy from Rona Therapeutics in a pact worth up to $1.16 billion, Quartz reported, alongside collaborations with Simcere Zaiming and Defand Therapeutics. ADCs, which deliver concentrated chemotherapy directly into tumors while sparing healthy tissue, have become one of the most competitive fields in oncology, Dow Jones noted via Morningstar, and Roche is plainly content to source early innovation from Jiangsu-based Hansoh.

Three Milestones Will Decide Whether $15 Billion Materializes

Three things will determine how much of the headline figure Hansoh ever sees. First, the identity and quality of the Roche-proposed targets, which will define the portfolio's real depth. Second, the readout of the global Phase Ia studies Hansoh is contracted to deliver, since those data trigger Roche's full takeover. And third, whether Hansoh exercises its option to co-develop up to two programs outside Greater China, which would enlarge its share of any eventual global product. Biobucks are promises; Phase Ia data will decide how many come due.